- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02401347
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes
Study Overview
Status
Intervention / Treatment
Detailed Description
Talazoparib (BMN 673) is a novel, dual-mechanism PARP inhibitor that potently inhibits the PARP enzyme and effectively traps PARP on DNA. Talazoparib has shown promising single-agent anti-tumor efficacy in several BRCA1/2 mutation-associated advanced cancers. The efficacy of PARP inhibition in BRCA1/2 wild-type TNBC with homologous recombination (HR) defects and in breast tumors with mutations in other non-BRCA1/2 HR pathway genes is currently unknown.
This phase 2 trial explores the activity of single agent talazoparib in BRCA1/2 wild-type BC patients using an optimal Simon two-stage design. Eligible subjects will be assigned to one of two parallel cohorts: 1) Cohort A: Subjects (n=29) with advanced TNBC with underlying HR defects as assessed by the HRD assay and, 2) Cohort B: Subjects (n=29) with advanced HER2-negative BC with a somatic or germline mutation in a non-BRCA1/2 HR pathway gene. Gene mutations of interest are: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes (FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford Medicine at Stanford University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- No deleterious germline BRCA1 or BRCA2 mutation based on full sequencing and comprehensive rearrangement testing at an external reference laboratory; patients with variants of unknown significance will be eligible
- Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
- Must have progressed on at least 1 prior chemotherapy regimen for the treatment of advanced breast cancer; there is no upper limit on the number of prior therapies
- If prior platinum agent (eg, carboplatin or cisplatin) has been administered, no evidence of progression, or within 8 weeks of stopping platinum treatment
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT ≤ 5 x ULN
- Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's syndrome)
- Calculated creatinine clearance ≥ 30 mL/min or serum creatinine ≤ 1.5 mg/dL
- Hemoglobin ≥ 9.0 g/dL with last transfusion at least 14 days before day 1 of study drug
- Absolute neutrophil count (ANC) ≥ 1500/mm^3
- Platelet count ≥ 100,000/mm^3
- Able to take oral medications
- Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
- Sexually active patients of childbearing potential must be willing to use an acceptable method of contraception such as an intrauterine device or double barrier contraception during treatment and for 30 days after the last dose of study drug
- Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to have additional serum pregnancy tests during the study; females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy
- Willing and able to comply with all study procedures
COHORT A SPECIFIC ELIGIBILITY CRITERIA:
- Histologically-confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor ≤ 5%, progesterone receptor ≤ 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH])
- An homologous recombination deficiency (HRD) score ≥ 42 on the HRD Assay as assessed on a tumor biopsy sample; in the case that obtaining an adequate metastatic tumor biopsy is not possible, we will assess the HRD score from the primary breast tumor
COHORT B SPECIFIC ELIGIBILITY CRITERIA:
- Histologically-confirmed metastatic or recurrent HER2-negative (via IHC or FISH) breast cancer or other histologically-confirmed metastatic solid tumor
- Deleterious germline or somatic mutation implicated in the homologous recombination (HR) pathway, excluding BRCA1 or BRCA2, based on germline multiplex gene testing or direct tumor next generation DNA sequencing. Genes of interest include: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, Rad51c, Rad51d, MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, plus other HR-related genes at the discretion of the primary investigators.
EXCLUSION CRITERIA:
- Any patient with a deleterious mutation in BRCA1 or BRCA2
- Hormone receptor positive and/or HER2 positive breast cancer (Cohort A only)
- HER2 positive breast cancer (Cohort B only)
- Prior treatment with a PARP inhibitor
- Non-measurable disease only
- Pregnant or nursing patients
- Any anti-cancer therapy within the past 21 days of the first day of treatment
Brain or central nervous system (CNS) metastases
- Exception: Adequately treated brain metastases documented by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan that have not progressed since previous scans and do not require corticosteroids (except prednisone ≤ 5 mg/day or equivalent) for management of CNS symptoms. A repeated CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases
- Subjects with leptomeningeal carcinomatosis are not permitted
- Other malignancy that is either active or for which patient has received treatment in the last five years excluding non-melanoma skin cancer and carcinoma in situ of the cervix
- Radiation therapy in the last 14 days
- Known to be human immunodeficiency virus positive
- Known active hepatitis C virus
- Known active hepatitis B virus
- Use of any investigational product or investigational medical device within 28 days before day 1 of study drug
- Major surgery requiring a prolonged hospitalization or recovery within 21 days before day 1 of study drug
Concurrent disease or condition that would interfere with study participation or safety, such as any of the following:
- Active, clinically significant infection either grade > 2 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 or requiring the use of parenteral anti-microbial agents within 7 days before day 1 of study drug
- Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
- Known hypersensitivity to any of the components of BMN 673
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A - Triple-negative Breast Cancer
Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay. Participants receive talazoparib 1 mg by mouth daily. |
Participants receive Talazoparib tosylate at 1 mg by mouth daily.
Other Names:
|
Experimental: Cohort B - HER2-negative solid tumor
Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes. Participants receive talazoparib 1 mg by mouth daily. |
Participants receive Talazoparib tosylate at 1 mg by mouth daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response (OR)
Time Frame: up to 24 weeks
|
Objective response (OR) is a common measure of benefit. OR is defined as the number of participants who achieved complete response (CR) or partial clinical (PR), per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (v1.1). RECIST Criteria are assessed by physical measurement; magnetic resonance imaging (MRI); computed tomography (CT), positron emission tomography (PET)-CT; and/or X-rays, as follows:
|
up to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit (CB)
Time Frame: up to 24 weeks
|
Clinical benefit (CB) is a common measure of benefit. CB is defined as the number of participants who achieved complete response (CR); partial clinical (PR); or stable disease (SD), per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (v1.1). RECIST Criteria are assessed by physical measurement; magnetic resonance imaging (MRI); computed tomography (CT), positron emission tomography (PET)-CT; and/or X-rays, as follows:
|
up to 24 weeks
|
Progression-free Survival (PFS)
Time Frame: 1 year
|
Progression-free survival (PFS) is a common measure of benefit.
PFS means to remain alive with disease or tumor progression.
Progression was defined per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (v1.1) as any ≥20% increase in long diameter of the target lesions, and/or the appearance of any new lesion(s).
PFS is expressed as the number of participants who remained alive without progression after 1 year, a number without dispersion.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Melinda L Telli, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-31913
- NCI-2015-00036 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- BRS0050 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Breast Cancer
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Zhejiang Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingFemale Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
University Hospital TuebingenRecruitingAdvanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)Germany
-
Royal Marsden NHS Foundation TrustPfizer; Hoffmann-La RocheRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast CancerUnited Kingdom
-
NBE-Therapeutics AGCmed Clinical ServicesTerminatedTriple Negative Breast Cancer | Advanced Solid Tumor | Advanced CancerUnited States
-
National Center of Oncology, ArmeniaBRIU GmbHCompletedAdvanced Breast Cancer | Metastatic Breast CancerArmenia
Clinical Trials on Talazoparib Tosylate
-
Stanford UniversityPfizerRecruitingBreast Cancer | Advanced Breast CancerUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingProstate CancerUnited States
-
National Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin LymphomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Terminated
-
Roswell Park Cancer InstitutePfizerRecruitingAdvanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditionsUnited States
-
Center Trials & TreatmentBioGene PharmaceuticalWithdrawnBreast Neoplasm | Advanced or Recurrent Solid TumorsAlbania
-
Seoul National University HospitalRecruitingAdvanced Breast CancerKorea, Republic of
-
Taivex Therapeutics CorporationTerminatedAdvanced Refractory Solid TumorsTaiwan
-
Taivex Therapeutics CorporationActive, not recruitingAdvanced Refractory Solid TumorsTaiwan